Opendata, web and dolomites

MicroCaT SIGNED

Micro-tumor Guided Cancer Therapy Selection MicroCaT

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "MicroCaT" data sheet

The following table provides information about the project.

Coordinator
2CUREX A/S 

Organization address
address: FRUEBJERGVEJ 3
city: KOBENHAVN
postcode: 2100
website: www.2curex.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://www.2curex.com/investors/grants/
 Total cost 2˙986˙699 €
 EC max contribution 2˙986˙699 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2021-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    2CUREX A/S DK (KOBENHAVN) coordinator 2˙986˙699.00

Map

 Project objective

Every year around 350.000 patients in the EU are newly diagnosed with colorectal cancer (CRC). Although € 1.4 Billion are spent on CRC drugs, the majority of patients fail to respond to therapy because their individual tumor is resistant to the chosen treatment. These patients suffer from unwanted side effects and after two month are switched to another drug regime – giving rise to additional drug and hospital costs. 2cureX ApS, a Danish SME, has developed IndiTreat, an ex-vivo chemosensitivity test. The functional profiling test uses 3D-cellular “micro-tumors” prepared directly from a patient’s tumor. It allows the selection of the most effective and least toxic drug regimen for each individual patient prior to initiating treatment. For the oncologists and patients this greatly improves the probability of selecting an effective drug treatment. The main objective of MicroCaT is to clinically validate the benefits of IndiTreat in an interventional multi-national study with metastatic (stage IV) colorectal cancer patients. Demonstrating the clinical utility and cost effectiveness of IndiTreat will pave the way for uptake in EU clinical guidelines and reimbursement arrangements. Communication and dissemination of MicroCaT project activities will be key to raise the consciousness of this breakthrough innovation with clinicians, patients and health assessment authorities. Commercializing IndiTreat for CRC patients will enable 2cureX to significantly grow and expand its business. With the potential to predict therapy responses in all solid forms of cancer, the use of IndiTreat will eventually result in multi-millions of health care costs savings as well as improving the quality of life of cancer patients across Europe.

 Deliverables

List of deliverables.
Project website operational Websites, patent fillings, videos etc. 2019-07-23 15:16:47

Take a look to the deliverables list in detail:  detailed list of MicroCaT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MICROCAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MICROCAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More